SUPN today
$29.57+$0.37 (+1.25%)close Nov 13, 2026Trend
DailyDowntrend (confirmed)
4 hourLeaning Bearish
1 hourStrong Bullish
15 minBullish
5 minStrong Bearish
Daily trend turns up above $44.31
Key levels
Resistance$36.12
Resistance$32.20
Support$29.16
Support$25.92
Latest news & SEC filings
AnalystSupernus Pharmaceuticals receives bullish analyst coverage initiation
AnalystB of A Securities starts Supernus coverage with Buy rating and $47 price target
All SUPN news →About Supernus
Supernus is a pharmaceutical company that develops and sells medicines for central nervous system conditions. Its products treat conditions such as attention deficit hyperactivity disorder, migraine, and Parkinson's disease, and it also markets treatments for opioid use disorder. The company sells mainly in the United States, with additional operations in select markets including Australia, Canada, France, and Germany. Its customers are patients, prescribers, pharmacies, and healthcare payers.
Based on the company's 10-K filed Feb 26, 2026.
Nasdaq · Healthcare
SUPERNUS PHARMACEUTICALS, INC. (SUPN)
What Is the Price Target for SUPN?
SEPT Low Target
$67.00
SEPT Mid Target
$67.00
SEPT High Target
$67.00
Analyst Consensus
$67.00
Is SUPN a Buy or Sell Right Now?
Thesis
- •Revenue growing 8.6% YoY with ACCELERATING trend — accelerating momentum.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for SUPN.
Start Free Trial →Is SUPN Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
P/E Forward, P/B, Analyst Consensus
Fair Value
$60.45
25
Moat Score
NONE
3/9
Piotroski Score
4.7
Altman Z-Score
What Is Smart Money Doing with SUPN?
Insider Signal
SELLING
0 buys / 9 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
MEDIUM
Signal: NEUTRAL
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| NEWHALL CHARLES W III | director | Sale | 124,119 | - | Nov 2, 2026 |
| GEMAYEL GEORGES | director | Sale | 27,277 | - | Nov 2, 2026 |
| DEC TIMOTHY C | officer | Sale | 9,129 | - | Nov 2, 2026 |
| GEMAYEL GEORGES | director | Buy | 42,009 | - | Nov 2, 2026 |
| Khattar Jack A. | director officer | Buy | 1,937,986 | - | Nov 2, 2026 |
| Khattar Jack A. | director officer | Buy | 1,475,569 | - | Nov 2, 2026 |
| DEC TIMOTHY C | officer | Buy | 14,059 | - | Nov 2, 2026 |
| Bhatt Padmanabh P. | officer | Buy | 28,702 | - | Nov 2, 2026 |
| Rubin Jonathan | officer | Sale | 13,979 | - | Nov 2, 2026 |
| Mottola Frank | officer | Sale | 19,544 | - | Nov 2, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →SUPN Growth Story
Revenue YoY
8.6%
3yr Revenue CAGR
2.5%
EPS Growth YoY
-151.52%
FCF Growth YoY
-73.1%
Revenue Trend
ACCELERATING
Dark Pool Trades for SUPN
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for SUPN, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 14:39:30 | $29.21 | 5,230 | $$153K | BUY |
| 21:00:36 | $29.20 | 5,896 | $$172K | SELL |
| 21:00:16 | $29.20 | 1,098 | $$32K | SELL |
| 21:00:14 | $29.20 | 1,865 | $$54K | SELL |
| 21:00:13 | $29.20 | 57,500 | $$1.7M | SELL |
5 dark pool trades shown · $$2.1M preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for SUPERNUS PHARMACEUTICALS, INC. (SUPN) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →SUPN — frequently asked questions
What is SUPN stock price today?
SUPERNUS PHARMACEUTICALS, INC. (SUPN) is at $29.57, up 1.25% (+$0.37) at the Nov 13, 2026 close.
Why is SUPN stock moving today?
Latest SUPN news — Nov 9, 2026: Supernus Pharmaceuticals receives bullish analyst coverage initiation · Nov 9, 2026: B of A Securities starts Supernus coverage with Buy rating and $47 price target
What is the SUPN price target?
The average analyst price target for SUPN is $67.00, ranging from $67 to $67, based on 1 analysts. Latest: Cantor Fitzgerald maintains on Jul 9, 2026.
What do analysts rate SUPN?
Analyst ratings for SUPN: 0 Buy, 1 Hold, 0 Sell — consensus Hold.
Did SUPN beat earnings?
SUPN last reported on Oct 29, 2026: EPS $0.35 vs $0.49 expected — a miss of 28.6%.
Does SUPN pay a dividend?
SUPN does not currently pay a dividend.
What are SUPN support and resistance levels?
Support: $29.16, $25.92. Resistance: $32.20, $36.12, $39.67.
What are insiders doing with SUPN?
Insider activity: SELLING, 0 buys and 9 sells in the last 90 days.
What is the latest news on SUPN?
Nov 9, 2026: Supernus Pharmaceuticals receives bullish analyst coverage initiation · Nov 9, 2026: B of A Securities starts Supernus coverage with Buy rating and $47 price target